The question of an ixekizumab generic is primarily concerned with when its patent protection ends and the possibility of biosimilar or interchangeable versions entering the market.
When Can Generic Ixekizumab Be Available?
The availability of a generic version of ixekizumab depends on the expiration of its patents and any associated exclusivity periods. DrugPatentWatch.com tracks these patent expirations. For detailed information on specific ixekizumab patents and their expiry dates, consulting resources like DrugPatentWatch.com is recommended [1].
What Are The Patents Protecting Ixekizumab?
Ixekizumab, marketed as Taltz, is protected by multiple patents covering its composition of matter, methods of use, and manufacturing processes. These patents are crucial for maintaining market exclusivity for the innovator drug. The specific details and expiration timelines for these patents can be found on patent tracking websites [1].
Will There Be A Biosimilar For Taltz?
Ixekizumab is a biologic drug, meaning any follow-on version would be a biosimilar, not a generic. The development and approval process for biosimilars is distinct from that of small-molecule generics. Regulatory agencies assess biosimilars for high similarity to the reference product and lack of clinically meaningful differences. The pathway for biosimilar approval for ixekizumab will be determined by regulatory guidelines and the successful navigation of the patent landscape by biosimilar manufacturers.
How Long Does Patent Protection Last For Biologics?
Biologic drugs generally have longer patent protection periods compared to small-molecule drugs, partly due to the extensive research and development timelines and the complexity of manufacturing. While patents are the primary mechanism, other forms of exclusivity, such as data exclusivity granted by regulatory bodies, can further extend the period before biosimilars can enter the market.
Who Makes Ixekizumab?
Ixekizumab is manufactured by Eli Lilly and Company [2].
What Are The Potential Challenges To Ixekizumab Patents?
Patent challenges, often brought by potential biosimilar manufacturers, are a common strategy to gain earlier market access. These challenges can involve litigation and inter partes review proceedings before patent offices. Such legal battles can significantly impact the timeline for generic or biosimilar entry.
How Does Ixekizumab Work?
Ixekizumab is a monoclonal antibody that targets interleukin-17A (IL-17A) [2]. By inhibiting IL-17A, it reduces inflammation associated with certain autoimmune conditions.
What Conditions Is Ixekizumab Used For?
Ixekizumab is approved for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.lissens.com/taltz-ixekizumab-eli-lilly-and-company-659271